Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Genesis hires Shifeng Pan as CSO, names Paul Friedman chair

Plus: Gen1E names François Nader chairman, and updates from Iambic and Boundless

December 13, 2024 1:37 AM UTC

Genesis Therapeutics Inc. named Shifeng Pan CSO and Alla Ivanova SVP of engineering. Pan joined Genesis in April from Odyssey Therapeutics Inc.; Ivanova joined in November from Google. The company added that Paul Friedman, former CEO of Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) and Incyte Corp. (NASDAQ:INCY), became chairman in April. Genesis is using AI for small molecule discovery.

Rare and inflammatory diseases company Gen1E Lifesciences Inc. named François Nader chair. Nader is a senior adviser at Blackstone Life Sciences and was chairman of the board of BenevolentAI S.A. (Euronext:BAI) until May...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article